Literature DB >> 17368363

Surgical management of squamous cell carcinoma of the lip: analysis of a 10-year experience in 223 patients.

Miroslav Vukadinovic1, Zoran Jezdic, Milan Petrovic, Ljiljana M Medenica, Marko Lens.   

Abstract

BACKGROUND: The most common type of lip carcinoma is squamous cell carcinoma (SCC), accounting for approximately 90% of all oral malignancies. Currently, surgery and/or radiotherapy are considered the standards of care for SCC of the lip.
MATERIALS AND METHODS: We retrospectively analyzed medical records of patients diagnosed with SCC of the lip at the Clinic for Maxillofacial surgery at University of Belgrade (Belgrade, Serbia) during a period between 1991 and 2000.
RESULTS: A total of 223 patients with SCC of the lip were diagnosed and treated during a 10-year period. The overall male-to-female ratio was 5 to 0. The most frequently affected site was the lower lip (92.8%). Mean diameter of the tumor was 30.1 mm (range, 5 to 80 mm). Neck lymph node metastases at presentation was detected in 26.5% of patients, who subsequently underwent neck dissection. We observed a linear trend in the association between the size of the tumor and the clinical stage of the neck (chi2 = 15.1; df = 1; P < .0001). Different surgical techniques were used for reconstruction of the lip defect after tumor removal. After a median follow-up of 56 months (range, 15 to 78 months), local recurrence occurred in 10.8% of patients while regional metastases developed in 4.5% of patients. Mortality from SCC of the lip was only 2.2%.
CONCLUSION: SCC of the lip generally has a favorable outcome. Recently, there have been no major advances in lip reconstruction but rather continued improvement on accepted techniques. Early detection is essential for the successful treatment of SCC of the lip, which requires a multidisciplinary approach.

Entities:  

Mesh:

Year:  2007        PMID: 17368363     DOI: 10.1016/j.joms.2006.03.054

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  7 in total

1.  Squamous cell carcinoma of the lip: survival analysis with long-term follow-up.

Authors:  Kerem Ozturk; Sercan Gode; Umut Erdogan; Serdar Akyildiz; Fazil Apaydin
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-03       Impact factor: 2.503

2.  Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer.

Authors:  Agnes Assao; Suely Nonogaki; José Roberto Pereira Lauris; André Lopes Carvalho; Clóvis Antônio Lopes Pinto; Fernando Augusto Soares; Luiz Paulo Kowalski; Denise Tostes Oliveira
Journal:  Clin Oral Investig       Date:  2016-09-14       Impact factor: 3.573

3.  Surgical management of lip cancer.

Authors:  A Moretti; F Vitullo; A Augurio; A Pacella; A Croce
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-02       Impact factor: 2.124

4.  Surgical management of squamous cell carcinoma of the lower lip: an experience of 109 cases.

Authors:  Wenhao Rena; Yin Lia; Changyang Liua; Cui Qianga; Linmei Zhang; Ling Gaoa; Zhi Wangb; Keqian Zhia
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-07-01

5.  Metastatic Squamous Cell Carcinoma of the Lower Lip: Analysis of the 5-Year Survival Rate.

Authors:  Tommaso Agostini; Giuseppe Spinelli; Francesco Arcuri; Raffaella Perello
Journal:  Arch Craniofac Surg       Date:  2017-06-26

6.  Epidemiology and survival outcomes of lip, oral cavity, and oropharyngeal squamous cell carcinoma in a southeast Brazilian population.

Authors:  B-V Louredo; P-A Vargas; M-E Pérez-de-Oliveira; M-A Lopes; L-P Kowalski; M-P Curado
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-05-01

7.  Pulsed Dose Rate Brachytherapy of Lip Carcinoma: Clinical Outcome and Quality of Life Analysis.

Authors:  Radouane El Ayachy; Roger Sun; Kanta Ka; Adrien Laville; Anne-Sophie Duhamel; Anne Tailleur; Isabelle Dumas; Sophie Bockel; Sophie Espenel; Pierre Blanchard; Yungan Tao; Stéphane Temam; Antoine Moya-Plana; Christine Haie-Meder; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2021-03-19       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.